A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer

被引：0
|
作者：
Daniel J. Renouf
Stephen Welch
Malcolm J. Moore
Monika K. Krzyzanowska
Jennifer Knox
Ronald Feld
Geoffrey Liu
Helen MacKay
Jennifer Petronis
Lisa Wang
Eric Chen
机构：
[1] University Health Network-Princess Margaret Hospital,Department of Medical Oncology and Hematology
[2] London Regional Cancer Centre,Department of Medical Oncology
[3] Princess Margaret Hospital,Department of Biostatistics
[4] University Health Network,Department of Medical Oncology
[5] British Columbia Cancer Agency,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Colorectal cancer; Capecitabine; Irinotecan; Bevacizumab; Phase II;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1339 / 1344
页数：5
相关论文
共 50 条
  • [1] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
  • [2] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [4] Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer
    Cassinello, Javier
    Valero Alvarez, Jose
    Garcia Lopez, Maria Jose
    Pujol, Eduardo
    Colmenarejo, Antonio
    Segovia, Femando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    CLINICAL COLORECTAL CANCER, 2006, 5 (06) : 429 - 435
  • [5] Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
    Kozuch, Peter
    Malamud, Steve
    Wasserman, Carrie
    Homel, Peter
    Mirzoyev, Takhir
    Grossbard, Michael
    CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 38 - 42
  • [6] Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer
    Pavia, OA
    Cangiano, J
    Crisostomo, R
    Caceres, W
    Barranco, E
    Wright, M
    Antonia, T
    Antonia, S
    Sullivan, D
    Garrett, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 307S - 307S
  • [7] A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
    Hong, Yong Sang
    Lee, Sung Sook
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Kang, Yoon-Koo
    Shin, Sang Joon
    Ahn, Joong Bae
    Jung, Kyung Hae
    Im, Seock-Ah
    Kim, Tae-You
    Kim, Jee Hyun
    Park, Young Suk
    Kim, Tae Won
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 19 - 23
  • [8] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [9] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [10] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Garcia Alfonso, P.
    Chaves, M.
    Munoz Martin, A.
    Salud Salvia, A.
    Vilchez, R.
    Yuste, A.
    Gravalos Castro, C.
    Queralt Merino, B.
    Gonzalez Flores, E.
    Lopez Ladron, A.
    Losa, F.
    Oltra Ferrando, A.
    Gomez Reina, M. J.
    Campos, J. M.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345